NJ State Employees Deferred Compensation Plan’s Apollo Endosurgery, Inc. APEN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-130,000
| Closed | -$1.29M | – | 500 |
|
|
2023
Q1 | $1.29M | Hold |
130,000
| – | – | 0.2% | 121 |
|
|
2022
Q4 | $1.3M | Hold |
130,000
| – | – | 0.21% | 121 |
|
|
2022
Q3 | $716K | Hold |
130,000
| – | – | 0.12% | 185 |
|
|
2022
Q2 | $475K | Hold |
130,000
| – | – | 0.08% | 264 |
|
|
2022
Q1 | $787K | Hold |
130,000
| – | – | 0.11% | 194 |
|
|
2021
Q4 | $1.1M | Hold |
130,000
| – | – | 0.14% | 169 |
|
|
2021
Q3 | $1.18M | Hold |
130,000
| – | – | 0.16% | 138 |
|
|
2021
Q2 | $1.05M | Hold |
130,000
| – | – | 0.14% | 158 |
|
|
2021
Q1 | $716K | Hold |
130,000
| – | – | 0.1% | 213 |
|
|
2020
Q4 | $442K | Hold |
130,000
| – | – | 0.07% | 290 |
|
|
2020
Q3 | $220K | Hold |
130,000
| – | – | 0.04% | 390 |
|
|
2020
Q2 | $211K | Hold |
130,000
| – | – | 0.04% | 401 |
|
|
2020
Q1 | $250K | Hold |
130,000
| – | – | 0.06% | 329 |
|
|
2019
Q4 | $371K | Hold |
130,000
| – | – | 0.06% | 347 |
|
|
2019
Q3 | $433K | Hold |
130,000
| – | – | 0.08% | 286 |
|
|
2019
Q2 | $423K | Hold |
130,000
| – | – | 0.08% | 323 |
|
|
2019
Q1 | $486K | Buy |
130,000
+10,000
| +8% | +$35K | 0.09% | 283 |
|
|
2018
Q4 | $414K | Buy |
120,000
+4,000
| +3% | +$19.8K | 0.09% | 279 |
|
|
2018
Q3 | $832K | Sell |
116,000
-38,000
| -25% | -$295K | 0.14% | 164 |
|
|
2018
Q2 | $1.07M | Sell |
154,000
-2,000
| -1% | -$12.4K | 0.19% | 116 |
|
|
2018
Q1 | $959K | Buy |
+156,000
| New | +$983K | 0.17% | 150 |
|
NJ State Employees Deferred Compensation Plan's APEN Position: Q2 2023 in Review
NJ State Employees Deferred Compensation Plan sold out of Apollo Endosurgery, Inc. (APEN) in Q2 2023, closing a stake of 130,000 shares — an estimated $1.29M sold.
NJ State Employees Deferred Compensation Plan first reported a position in APEN in Q1 2018 and held it in 21 quarters. The position peaked at $1.3M in Q4 2022. 0 funds tracked by Wall St. Rank hold APEN as of Q2 2023.
- NJ State Employees Deferred Compensation Plan reported no remaining Apollo Endosurgery, Inc. position as of Q2 2023 after selling out during the quarter.
- NJ State Employees Deferred Compensation Plan sold 130,000 Apollo Endosurgery, Inc. shares in Q2 2023, an estimated $1.29M.
- NJ State Employees Deferred Compensation Plan first reported a position in Apollo Endosurgery, Inc. in Q1 2018 and held it in 21 quarters.
- NJ State Employees Deferred Compensation Plan's Apollo Endosurgery, Inc. position peaked at $1.3M in Q4 2022.
- 0 funds tracked by Wall St. Rank held Apollo Endosurgery, Inc. as of Q2 2023.
Based on NJ State Employees Deferred Compensation Plan's 13F filing for Q2 2023, filed 2 Aug 2023.